InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.380 -0.435 (-53.37%)+
Announcement
Release
18 Feb 2026 8:16AM
Price at Release
$0.815
Full Release
download
Summary
Healius Limited announced its financial results for the first half of the fiscal year 2026 with a reported group revenue increase of 3.8% to $688.1 million. The company achieved an underlying EBITDA of $122.2 million, marking a 13.1% rise, and an underlying EBIT of $7.9 million, compared to a loss in the same period the previous year. Pathology revenue saw a growth of 3.5%, and Agilex revenue increased by 16.0%. Cost management efforts led to a minimal cost increase of 1.9%, with significant improvements due to productivity measures, including a headcount reduction and technological optimizations. A major digital transformation initiative is underway, with achievements including the launch of AI co-workers and digital solutions for pathology services. Additionally, Healius secured a contract with the Australian Department of Defence, valued at approximately $60 million over five years. The company anticipates high single-digit EBIT margins by June 2027, driven by continuing volume improvements and cost-saving measures.
Key Points
  • Group revenue up 3.8% to $688.1 million.
  • Underlying EBITDA up 13.1% to $122.2 million.
  • Underlying EBIT $7.9 million from a loss in 1H25.
  • Pathology revenue increased by 3.5%.
  • Agilex revenue grew by 16.0%.
  • Cost management limited increase to 1.9%.
  • Implementation of AI and digital solutions.
  • Contract with Australian Department of Defence worth $60 million.
  • High single-digit EBIT margins expected by June 2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.